Atorvastatin population pharmacokinetics in a real‐life setting: Influence of genetic polymorphisms and association with clinical response-Reference-Cited by-同舟云学术

Atorvastatin population pharmacokinetics in a real‐life setting: Influence of genetic polymorphisms and association with clinical response

Published:2021-11-23 Issue: Volume: Page:
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Stillemans Gabriel¹²,Paquot Adrien³,Muccioli Giulio G.³,Hoste Emilia¹²,Panin Nadtha²,Åsberg Anders⁴,Balligand Jean‐Luc⁵⁶,Haufroid Vincent²⁷,Elens Laure¹²

Affiliation:

1. Integrated PharmacoMetrics, PharmacoGenomics and PharmacoKinetics Louvain Drug Research InstituteUniversité catholique de Louvain Brussels Belgium

2. Louvain Centre for Toxicology and Applied Pharmacology Institut de Recherche Expérimentale et CliniqueUniversité Catholique de Louvain Brussels Belgium

3. Bioanalysis and Pharmacology of Bioactive Lipids Louvain Drug Research InstituteUniversité Catholique de Louvain Brussels Belgium

4. Department of Pharmacology School of Pharmacy University of Oslo Oslo Norway

5. Pole of Pharmacology and Therapeutics Institut de Recherche Expérimentale et CliniqueUniversité Catholique de Louvain Brussels Belgium

6. Department of Internal Medicine Cliniques Universitaires Saint‐Luc Brussels Belgium

7. Department of Clinical Chemistry Cliniques Universitaires Saint‐Luc Brussels Belgium

Funder

Fonds pour la Formation à la Recherche dans l’Industrie et dans l’Agriculture

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13185

Reference58 articles.

1. Low‐density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel;Ference BA;Eur Heart J,2017

2. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR);Piepoli MF;Eur Heart J,2016

3. Atorvastatin for lowering lipids;Adams SP;Cochrane Database Syst Rev,2015

4. Statin‐induced myopathy: a review and update;Abd TT;Expert Opin Drug Saf,2011

5. Clinical pharmacokinetics of atorvastatin;Lennernas H;Clin Pharmacokinet,2003

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The need for a change in medical research thinking. Eco-systemic research frames are better suited to explore patterned disease behaviors;Frontiers in Medicine;2024-06-03

2. Atorvastatin-associated myotoxicity: A toxicokinetic review of pharmacogenetic associations to evaluate the feasibility of precision pharmacotherapy;Clinical Biochemistry;2024-02

3. Population Pharmacokinetics of Atorvastatin in High‐Altitude and Plain Patients with Hyperlipidemic;The Journal of Clinical Pharmacology;2023-11-17

4. SLCO1B1 and CYP3A4 allelic variants associated with pharmacokinetic interactions and adverse reactions induced by simvastatin and atorvastatin used in Peru: Clinical implications;Journal of Pharmacy & Pharmacognosy Research;2023-11-01

5. Influence of pharmacogenetics on the diversity of response to statins associated with adverse drug reactions;Advances in Laboratory Medicine / Avances en Medicina de Laboratorio;2023-10-11